**GU Cancer Clinical Trials**

**UCI 16-19** ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy (Uchio)

**UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

**UCI 16-76** Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) (Mar)

**UCI 16-90** A Phase III, Multicenter, Randomized Study Of Atezolizumab (Anti−PD-L1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of An Androgen Synthesis Inhibitor And Failure Of, Ineligibility For, Or Refusal Of A Taxane Regimen (Mar)

**UCI 17-10** A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/ Prednisolone, Relative to Placebo plus Abiraterone plus Prednisone/ Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer (Mar)

**UCI 17-25** A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/ Prednisone) (Uchio)

**UCI 17-41** A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) (Uchio)

**UCI 17-86** Phase 1 Trial of Efficacy and Feasibility of Robot Assisted Salvage Pelvic Lymph Node Dissection (RS-PLND) or Robot Assisted Salvage Pelvic Mass Resection (RS-PMR) Post-Robot Assisted Radical Prostatectomy (Ahlering)

**ECOG-EAY131** Molecular Analysis for Therapy Choice (MATCH) (Seery)

**SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

**UCI 16-96** A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

**UCI 17-48** HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer (Uchio)

**For more details contact 1-877-UC-STUDY or ucstudy@uci.edu**

**Opening soon**

**Version 11/17**
GU Cancer Clinical Trials

- **Observational**
  - UCI 06-13 Evaluation of Predictive Signatures of Prostate Cancer (Mercola)
  - UCI 98-41 Outcomes and Assessment of Prostate Cancer at UCIMC (Ahlering)

- **Prevention**
  - UCI 14-65 Phase II Randomized, Placebo-Controlled Trial of PROSTVAC® (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active Surveillance (Uchio)
  - UCI 14-90 Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading (Mercola)

- **Epidemiologic**
  - UCI 17-40 Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response (Uchio)

- **Screening & Correlative**
  - UCI 15-70 Small Nucleolar RNAs (snoRNAs) And Alternative Splicing In Castration-Resistant Prostate Cancer: A Potential Role In Regulation Of Androgen Receptor Signaling (Zi)
  - UCI 16-01 Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (Nelson)
  - UCI 00-55 Retrospective Evaluation of Prostate Cancer Clinical and Pathological Outcomes (Ahlering)

**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

Version 11/17
For more details contact 1-877-UC-STUDY or ucstudy@uci.edu
**Opening soon**

For more details contact
1-877-UC-STUDY or ucstudy@uci.edu